Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Siok Ying Lee"'
Autor:
Tat Ming Ng, Li Wei Ang, Shi Thong Heng, Andrea Lay-Hoon Kwa, Jia En Wu, Xue Fen Valerie Seah, Siok Ying Lee, Jonathan Seah, Robin Choo, Poh Lian Lim, Koh Cheng Thoon, Maciej Piotr Chlebicki, Jyoti Somani, Tau Hong Lee, David C. Lye
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 12, Iss 1, Pp 1-13 (2023)
Abstract Objective The aim of this study was to describe the time series of broad-spectrum antibiotic utilisation and incidence of antibiotic-resistant organisms during the implementation of antimicrobial stewardship programmes (ASP) in Singapore. Me
Externí odkaz:
https://doaj.org/article/82d5d34288a5408b8d1886c18fa3577b
Autor:
Sreemanee Raaj Dorajoo, Chrystal Leandra Winata, Jessica Hui Fen Goh, Say Tat Ooi, Jyoti Somani, Lee Ying Yeoh, Siok Ying Lee, Chun Wei Yap, Alexandre Chan, Jung-woo Chae
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Chronic kidney disease (CKD) patients requiring intravenous vancomycin bear considerable risks of adverse outcomes both from the infection and vancomycin therapy itself, necessitating especially precise dosing to avoid sub- and suprathera
Externí odkaz:
https://doaj.org/article/dc003c5dde1a4148880e341d25a7cf57
Autor:
Chrystal Leandra Winata, Alexandre Chan, Say Tat Ooi, Chun Wei Yap, Jung-woo Chae, Jessica Hui Fen Goh, Sreemanee Raaj Dorajoo, Lee Ying Yeoh, Siok Ying Lee, Jyoti Somani
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in pharmacology, vol 10, iss JUN
Frontiers in Pharmacology
Frontiers in pharmacology, vol 10, iss JUN
Frontiers in Pharmacology
Background: Chronic kidney disease (CKD) patients requiring intravenous vancomycin bear considerable risks of adverse outcomes both from the infection and vancomycin therapy itself, necessitating especially precise dosing to avoid sub- and suprathera
Autor:
Lawrence Lee Soon-U, Siok Ying Lee, Claude J. Renaud, Say Tat Ooi, Kim-Hor Hee, Jessica Hui Fen Goh
Publikováno v:
Hemodialysis International. 20:253-260
Ceftazidime is a cost-effective antimicrobial against Gram-negative pathogens associated with sepsis in end-stage renal disease (ESRD) hemodialysis patients with potential for wider use with the advent of ceftazidime-avibactam. Dosing ceftazidime pos
Autor:
Siok-Ying Lee1, Chay-Leng Yeo2, Lee, Winnie H.3, Kwa, Andrea L.3, Liang-Piu Koh4, Li-Yang Hsu5 liyanghsu@yahoo.com
Publikováno v:
BMC Research Notes. 2011, Vol. 4 Issue 1, p42-45. 4p.
Autor:
Jessica Hui Fen, Goh, Siok Ying, Lee, Say Tat, Ooi, Lawrence, Lee Soon-U, Kim-Hor, Hee, Claude J, Renaud
Publikováno v:
Hemodialysis international. International Symposium on Home Hemodialysis. 20(2)
Ceftazidime is a cost-effective antimicrobial against Gram-negative pathogens associated with sepsis in end-stage renal disease (ESRD) hemodialysis patients with potential for wider use with the advent of ceftazidime-avibactam. Dosing ceftazidime pos
Autor:
Christine B Teng, Winnie Lee, Chay Leng Yeo, Siok Ying Lee, Tat Ming Ng, Siang Fei Yeoh, Wee Heng Lim, Andrea L Kwa, Koh Cheng Thoon, Say Tat Ooi, Thean Yen Tan, Li Yang Hsu, David C Lye, Maciej Piotr Chlebicki
Publikováno v:
Annals of the Academy of Medicine, Singapore. 41(1)
Autor:
Yi-Xin Liew, Prabha Krishnan, Chay-Leng Yeo, Thean-Yen Tan, Siok-Ying Lee, Wan-Peng Lim, Winnie Lee, Li-Yang Hsu, Network for Antimicrobial Resistance Surveillance Singapore
Publikováno v:
PLoS ONE
PLoS ONE, Vol 6, Iss 12, p e28751 (2011)
PLoS ONE, Vol 6, Iss 12, p e28751 (2011)
Background Inappropriate prescription of antibiotics may contribute towards higher levels antimicrobial resistance. A key intervention for improving appropriate antibiotic prescription is surveillance of prescription. This paper presents the results
Autor:
Hui Fen GOH, Jessica, Siok Ying LEE, Say Tat OOI, LEE SOON-U., Lawrence, Kim-Hor HEE, RENAUD, Claude J.
Publikováno v:
Hemodialysis International; Apr2016, Vol. 20 Issue 2, p253-260, 8p
Publikováno v:
BMC Research Notes
BMC Research Notes, Vol 4, Iss 1, p 42 (2011)
BMC Research Notes, Vol 4, Iss 1, p 42 (2011)
Background The use of newer azoles as prophylaxis in hematological patients undergoing stem cell transplantation or immunosuppressive chemotherapy has been shown to decrease the risk of developing invasive fungal disease (IFD). However, the cost-effe